These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 29575941)
1. Treatment outcomes of conventional or high-dose ranibizumab for vascularized pigment epithelial detachment based on lesion subtypes. Chan CK; Sarraf D; Abraham P Eur J Ophthalmol; 2018 Nov; 28(6):677-683. PubMed ID: 29575941 [TBL] [Abstract][Full Text] [Related]
2. Earlier therapeutic effects associated with high dose (2.0 mg) Ranibizumab for treatment of vascularized pigment epithelial detachments in age-related macular degeneration. Chan CK; Abraham P; Sarraf D; Nuthi AS; Lin SG; McCannel CA Eye (Lond); 2015 Jan; 29(1):80-7. PubMed ID: 25277305 [TBL] [Abstract][Full Text] [Related]
3. Response of vascular pigment epithelium detachment due to age-related macular degeneration to monthly treatment with ranibizumab: the prospective, multicentre RECOVER study. Clemens CR; Wolf A; Alten F; Milojcic C; Heiduschka P; Eter N Acta Ophthalmol; 2017 Nov; 95(7):683-689. PubMed ID: 28084038 [TBL] [Abstract][Full Text] [Related]
4. RETINAL PIGMENT EPITHELIAL TEAR AND ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY IN EXUDATIVE AGE-RELATED MACULAR DEGENERATION: Clinical Course and Long-Term Prognosis. Heimes B; Farecki ML; Bartels S; Barrelmann A; Gutfleisch M; Spital G; Lommatzsch A; Pauleikhoff D Retina; 2016 May; 36(5):868-74. PubMed ID: 26655607 [TBL] [Abstract][Full Text] [Related]
5. Variable response of vascularized pigment epithelial detachments to ranibizumab based on lesion subtypes, including polypoidal choroidal vasculopathy. Inoue M; Arakawa A; Yamane S; Kadonosono K Retina; 2013 May; 33(5):990-7. PubMed ID: 23446653 [TBL] [Abstract][Full Text] [Related]
6. Ranibizumab Treatment for Pigment Epithelial Detachment Secondary to Neovascular Age-Related Macular Degeneration: Post Hoc Analysis of the HARBOR Study. Sarraf D; London NJ; Khurana RN; Dugel PU; Gune S; Hill L; Tuomi L Ophthalmology; 2016 Oct; 123(10):2213-24. PubMed ID: 27566855 [TBL] [Abstract][Full Text] [Related]
7. Intravitreal ranibizumab for pigment epithelium detachment with subfoveal occult choroidal neovascularization: a prospective 24-month case series. Parodi MB; Iacono P; Papayannis A; Kontadakis SD; Cascavilla M; Pierro L; Gagliardi M; Bandello F Am J Ophthalmol; 2013 Jan; 155(1):103-108.e2. PubMed ID: 23022164 [TBL] [Abstract][Full Text] [Related]
8. Prognosti implications of pigment epithelial detachment in bevacizumab (avastin)-treated eyes with age-related macular degeneration and choroidal neovascularization. Freeman WR; Kozak I; Yuson RM; Nigam N; Cheng L; Mojana F Retina; 2011 Oct; 31(9):1812-8. PubMed ID: 21866073 [TBL] [Abstract][Full Text] [Related]
9. RETINAL PIGMENT EPITHELIAL TEAR AFTER INTRAVITREAL RANIBIZUMAB TREATMENT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Cho HJ; Kim HS; Yoo SG; Han JI; Lew YJ; Cho SW; Lee TG; Kim JW Retina; 2016 Oct; 36(10):1851-9. PubMed ID: 27074658 [TBL] [Abstract][Full Text] [Related]
10. Pigment epithelial detachment followed by retinal cystoid degeneration leads to vision loss in treatment of neovascular age-related macular degeneration. Schmidt-Erfurth U; Waldstein SM; Deak GG; Kundi M; Simader C Ophthalmology; 2015 Apr; 122(4):822-32. PubMed ID: 25578255 [TBL] [Abstract][Full Text] [Related]
12. Macular Morphology and Visual Acuity in the Second Year of the Comparison of Age-Related Macular Degeneration Treatments Trials. Sharma S; Toth CA; Daniel E; Grunwald JE; Maguire MG; Ying GS; Huang J; Martin DF; Jaffe GJ; Ophthalmology; 2016 Apr; 123(4):865-75. PubMed ID: 26783095 [TBL] [Abstract][Full Text] [Related]
13. Effectiveness of Intravitreal Injection of Ranibizumab for Neovascular Age-Related Macular Degeneration with Serous Pigment Epithelial Detachment. Zhao C; Zhang Z; Chen L; Wang F; Xu D Med Sci Monit; 2016 Mar; 22():833-9. PubMed ID: 26972376 [TBL] [Abstract][Full Text] [Related]
14. Fibrovascular pigment epithelial detachment is a risk factor for long-term visual decay in neovascular age-related macular degeneretion. Hoerster R; Muether PS; Sitnilska V; Kirchhof B; Fauser S Retina; 2014 Sep; 34(9):1767-73. PubMed ID: 24936942 [TBL] [Abstract][Full Text] [Related]
15. Prospective clinical trial of Intravitreal aflibercept treatment for PolypoIdal choroidal vasculopathy with hemorrhage or exudation (EPIC study): 6 month results. Kokame GT; Lai JC; Wee R; Yanagihara R; Shantha JG; Ayabe J; Hirai K BMC Ophthalmol; 2016 Jul; 16():127. PubMed ID: 27465105 [TBL] [Abstract][Full Text] [Related]
16. GOOD VISUAL OUTCOME AT 1 YEAR IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH PIGMENT EPITHELIUM DETACHMENT: Factors Influencing the Treatment Response. de Massougnes S; Dirani A; Mantel I Retina; 2018 Apr; 38(4):717-724. PubMed ID: 28368974 [TBL] [Abstract][Full Text] [Related]
17. Factors Influencing the Treatment Response of Pigment Epithelium Detachment in Age-Related Macular Degeneration. Dirani A; Ambresin A; Marchionno L; Decugis D; Mantel I Am J Ophthalmol; 2015 Oct; 160(4):732-8.e2. PubMed ID: 26144701 [TBL] [Abstract][Full Text] [Related]
18. RANIBIZUMAB IN PIGMENT EPITHELIAL TEARS SECONDARY TO AGE-RELATED MACULAR DEGENERATION: A Prospective Study. Larsen PP; Oishi A; Bedar MS; Heymer PKR; Clemens CR; König S; Gutfleisch M; Pauleikhoff D; Eter N; Wolf A; Holz FG; Krohne TU Retina; 2019 Dec; 39(12):2369-2377. PubMed ID: 30198967 [TBL] [Abstract][Full Text] [Related]